← Eichor
Study identifier: NCT05812950 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clinical and Cost-effectiveness of Group Schema Therapy for Complex Eating Disorders: the GST-EAT Study

Condition: Anorexia Nervosa · Atypical Anorexia Nervosa (Other Specified Eating Disorder) · Bulimia Nervosa  ·  Sponsor: Maastricht University

PhaseNA
Planned participants230
Who can joinAll sexes, 16 Years to no upper limit
Healthy volunteersNo

About this study

Amongst psychiatric illnesses, eating disorders (EDs) are notoriously difficult to treat and have a high mortality rate. The average duration of an ED is 6 years and for a majority of ED patients, the disorder will become chronic. Comorbid personality pathology such as negative core beliefs and early maladaptive schemas (EMS) are strongly related to ED severity and chronicity. Enhanced cognitive-behavioural therapy for eating disorders (CBT-E) is used as the first line transdiagnostic treatment for EDs. However, CBT-E is mainly symptom-focused and does not tap into these underlying core beliefs and EMS. Given the limited treatment effects of existing ED treatments, and the importance of comorbid personality pathology, there is an urgent need to examine more effective treatments for EDs. Group-schematherapy (GST) overcomes the limitations of CBT-E and preliminary results for treatment-resistant EDs are promising. However, robust evidence regarding the clinical and cost-effectiveness of GST for patients that do not benefit from CBT-E is not yet available. The central aim of this project is to investigate the clinical and cost-effectiveness of GST for EDs in patients with comorbid personality pathology, who do not show a clinically significant response in the first phase of CBT-E. This is relevant and important as studies examining the effectiveness of GST for EDs are scarce. This project is a joint research initiative of three academic centers (Dutch Universities), four large …

This description comes directly from the study's public registry record.

Talk to the study team

Jeffrey Roelofs, Dr.  ·  +31433881607  ·  j . roelofs @ maastricht university . nl

Suzanne Mares, Dr.  ·  +31688 933 5701  ·  s.mares@ggnet.nl

Always discuss trial participation with your own doctor first.

Locations (7)

GGz BreburgBreda, NetherlandsRecruiting
AccareGroningen, NetherlandsRecruiting
GGZ FrieslandLeeuwarden, NetherlandsRecruiting
GGNet AmarumNijmegen, NetherlandsRecruiting
GGz BreburgTilburg, NetherlandsRecruiting
Co-eurUtrecht, NetherlandsRecruiting
GGNet AmarumWarnsveld, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05812950